Charles River Labs Licenses CRISPR/Cas9 IP from ERS Genomics
Charles River Laboratories has expanded its available CRISPR/Cas9 offerings to include both technologies at the center of the bitter legal battle over who first invented the genome-editing application. Charles River has licensed from ERS Genomics nonexclusive access to ERS’s CRISPR/Cas9 patents, which are based on the technology that, in turn, ERS has licensed from holders of a European patent granted in March —namely the Regents of the University of California (UC), the University of Vienna, and Emmanuelle Charpentier, Ph.D., a director at the Max-Planck Institute in Berlin. The European patent holders are appealing a February 15 decision by the Patent Trial and Appeal Board (PTAB), which sided with the Broad Institute of MIT and Harvard in the bitter legal battle over who invented the gene-editing platform. The PTAB found “no interference in fact” between 12 patents related to CRISPR technology that list as inventor Feng Zhang, Ph.D., ...
Original Article: Charles River Labs Licenses CRISPR/Cas9 IP from ERS Genomics
